Procedures:

Latisse Launch

Dating back to the time of the Egyptians, eyelashes and eye makeup have been important mainstays of beauty.

Today, mascara continues to play a central role in a women's daily make up routine. The desire for fuller and longer eyelashes is so common that the sale of mascara makes up a billion dollar industry.

Like some other great medical discoveries, the discovery of a medication that lengthens eyelashes was an accident. Patients who were being treated for elevated eye pressure-glaucoma with LumiganTM eye drops began to notice a lengthening and thickening of the eyelashes. This prompted Allergan to research this finding. Bimatoprost 0.03% solution is the active ingredient. It is a prostaglandin analog which scientists believe, in a solution, increases the numbers of hairs in the growth phase of the eyelash cycle. Used as a daily eye drop to treat glaucoma, some patients noticed a darkening of the colored part of the eye (iris), as well as the surrounding eyelid skin. When the FDA studies were done with LatisseTM, the solution was applied with a small applicator to the upper eyelids. Slight darkening of the skin at the base of the eyelashes was found to occur creating a similar effect as eye liner. No darkening of the colored part of the eye occurred with LatisseTM most likely due to the fact that less solution was applied to the eye area and was applied to the eyelashes using a small applicator.

In 2009, the Food and Drug Administration approved LatisseTM to treat hypotricosis, short and thin eyelashes, by increasing their growth, including darkness, thickness and length.

The illustration depicts the growth cycle of the eyelash using LatisseTM. By the end of the 16 week trial, 78% of the patients experienced a noticeable change from when they started. On average, patients using LatisseTM experienced a 25% increase in length, 106% increase in fullness, and 18% increase in darkness of the eyelash.

Patients with allergies to any of the ingredients in LatisseTM should not use it. If you are currently being treated for glaucoma you should consult your eye doctor before beginning treatment with LatisseTM. Studies have not been performed on pregnant or breast feeding patients, therefore, Dr Maloney does not recommend use. There is a potential for hair growth to occur in areas where LatisseTM is repeatedly applied. Some reports have involved patients using it “off label” to grow thicker eyebrows.

The LatisseTM contains a preservative benzalkonium chloride which may be absorbed by soft contact lenses. Therefore, the manufacturer recommends removing the contact lenses prior to applying the LatisseTM. One may reinsert contact lenses 15 minutes after application. Less than 4% of patients may experience itching, redness, darkening of the skin, eye irritation, or dry eyes.

BaseLine:

Week 4

Week 8

Week 12

Week 16

LATISSE™ Consent Form

LATISSE™ is approved by the Food and Drug Administration (FDA) for the treatment of thin or short eyelashes.
If you have a history of abnormal intraocular pressure (IOP), you should inform Dr. Maloney and only use LATISSE™ with close supervision of your eye doctor.

Do not use LATISSE™ solution if you are allergic to one of its ingredients.

LATISSE™ solution is intended for use on the skin of the upper eyelid margins at the base of the eyelashes.

DO NOT OVERDOSE. More is not better. DO NOT APPLY to the lower eyelid.

LATISSE™ use may cause darkening of the eyelid skin which may be reversible. Although not reported in clinical studies, LATISSE™ use may also cause increased brown pigmentation of the colored part of the eye which is likely to be permanent.

Inform Dr. Maloney if you are already using LATISSE™, especially if you have a history of eye pressure problems. You should also tell anyone conducting an eye pressure screening that you are using LATISSE™.

The most common side effects after using LATISSE™ solution are an itching sensation in the eyes and / or eye redness. This was reported in approximately 4% of patients.

LATISSE™ solution may cause other less common side effects which typically occur on the skin close to where LATISSE™ is applied, or in the eyes. These include skin darkening, eye irritation, dryness of the eyes, and redness of the eyelids.
Some patients may experience no change in the eyelash growth with LATISSE™.

Hair growth outside of the target area may develop with repeated contact.

Contact lenses should be removed prior to application. One may reinsert contact lenses 15 minutes after application.
Because the effect of applying LATISSE™ to the eyelids of pregnant or breast feeding patients is unknown, Dr. Maloney does not recommend use.

I understand that Dr. Maloney is a consultant and teaching center for Allergan, the manufacturer of LATISSE™. Full prescribing information has been provided to me by Dr. Maloney.

I agree to hold Brian P. Maloney, M.D., and the Maloney Center, P.C. harmless for not meeting my expectations since I am choosing to receive this treatment.

This product is not returnable. All sales are final.